English

BIOHIT PLC. HAS CONCLUDED AN IMPORTANT C

Report this content 
BIOHIT PLC.  STOCK EXCHANGE RELEASE     7.8.2000 at 15:00     1 (1)

BIOHIT PLC. HAS CONCLUDED AN IMPORTANT CO-OPERATION AGREEMENT

Biohit  Plc.,  operating  within the areas of biotechnology  and  high
technology, concluded on August 3, 2000 with the U.S. company  Bio-Tek
Instruments,  Inc.  an  agreement  on  the  basis  of  which   Bio-Tek
Instruments,  Inc. will already during fall 2000 begin to  deliver  to
Biohit   instruments  employing  the  vertical  measurement  principle
together  with their accessories. These instruments will  be  used  in
research,  industrial and diagnostic laboratories for the analysis  of
samples. Biohit's new co-operation partner Bio-Tek Instruments,  Inc.,
a  part of Lionheart Technologies, Inc., designs, develops and markets
laboratory  instruments,  software, integrated  system  solutions  and
reagents throughout the world.

Co-operation  with Bio-Tek Instruments, Inc. enables  Biohit  Plc.  to
offer  for  its  customers worldwide complete analyzing  systems.  The
systems  will  be  comprised of liquid handling  products,  diagnostic
tests,  instruments  used for analyzing the test results  as  well  as
maintenance  and  training services. In accordance with  its  business
plan Biohit Plc. is now able to offer total product solutions for  its
customers  which  will promote the attractiveness  and  sales  of  all
Biohit products.

Biohit's  instruments and their accessories together with  its  liquid
handling  products will speed up and reinforce the entry  of  Biohit's
diagnostic  products  on  the  international  markets.  The  range  of
Biohit's diagnostic tests includes a unique test panel, which  enables
the  detection of patients who are at high risk of gastric  cancer  or
peptic  ulcer from a blood sample. The test panel can be considered  a
major advance, and it is the only test on the market which enables the
holistic  analysis  of gastric diseases on the basis  a  blood  sample
without needing to perform gastroscopy. The test panel contributes  to
the treatment of gastric cancer and makes it more economical since the
gastroscopies can be directed to only those patients who, on the basis
of  the  results of the new test panel, have been determined to belong
to  the  risk groups. Thus, gastric cancer or its premalignant  phases
can  be  detected  at  an  early  stage  and,  as  a  result,  treated
effectively. It has been estimated that the global market potential of
the  Company's diagnostic tests employing biotechnology totals to  USD
5,0 billion.

Additional information:  Osmo Suovaniemi, President & CEO, tel: +358-9-
                         773 861, direct: +358-9-773 86 250, mobile:
                         +358-50 556 5605, fax: +358-9-773 86 205

                         http://www.biohit.com

Distribution:            Helsinki Exchanges
                         The Financial Supervisory Authority
                         Press

Subscribe